Shots:

• The P-Ib/II trial evaluates the safety and preliminary efficacy of onvansertib + Folfiri and Avastin in 2L treatment of patients with KRAS-mutated mCRC
• As of July 2- 2021- 42% patients achieved a partial response at RP2D (15 mg/m² dose); confirmed PR (37%); ORR (5-13%); mPFS has not yet reached. Additionally- 38% patients achieved an initial PR who treated at all dose levels (12 mg/m²- 15 mg/m²- 18 mg/m²); confirmed PR (31%); mPFS (9.4mos.) across all response-evaluable patients
• Additionally- partial responses were observed across different KRAS mutation variants. The combination is well-tolerated and showed the synergistic effect

| Ref: Cardiff Oncology | Image: PharmaLive